The Manufacturers Life Insurance Company Purchases Shares of 116,132 Illumina, Inc. $ILMN

The Manufacturers Life Insurance Company acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 116,132 shares of the life sciences company’s stock, valued at approximately $20,419,000. The Manufacturers Life Insurance Company owned approximately 0.08% of Illumina at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ILMN. Fiduciary Financial Advisors acquired a new stake in Illumina during the second quarter valued at approximately $26,000. L2 Asset Management LLC acquired a new position in Illumina in the second quarter worth approximately $2,576,000. Patient Capital Management LLC bought a new position in shares of Illumina in the second quarter valued at $60,717,000. Cibc World Market Inc. bought a new position in shares of Illumina in the second quarter valued at $2,260,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Illumina during the 2nd quarter valued at $5,098,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 1.3%

NASDAQ ILMN opened at $227.69 on Friday. The firm’s 50 day moving average price is $192.98 and its two-hundred day moving average price is $155.18. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The stock has a market cap of $34.38 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ILMN shares. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Barclays upped their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Guggenheim lifted their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $188.40.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 457,858 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,034,688 shares of company stock worth $417,970,281 over the last three months. 2.90% of the stock is owned by insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.